<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The task of improving patient and caregiver satisfaction in the management of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) poses many challenges for physicians and patient care teams </plain></SENT>
<SENT sid="1" pm="."><plain>Advances in the understanding of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> biology have resulted in the approval of 3 agents for the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> by the US Food and Drug Administration (FDA) in the past decade </plain></SENT>
<SENT sid="2" pm="."><plain>However, according to a retrospective physician survey, the majority of recently diagnosed patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> still receive supportive care only </plain></SENT>
<SENT sid="3" pm="."><plain>Interestingly, a survey performed in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> suggests that patient understanding of treatment goals and prognosis is often limited, with a third of patients reporting that prognosis was not discussed with their physician </plain></SENT>
<SENT sid="4" pm="."><plain>Efforts to improve patient awareness of their disease severity and establishing clear treatment goals are crucial for setting up an individualized treatment plan and ensuring optimal patient and caregiver satisfaction </plain></SENT>
</text></document>